NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-173-2020-0-HK-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 HK EP 62023083439.7 Pending
NCI E-027-2022-0-PC-01 TOPOISOMERASE Ill (TOP3) INHIBITORS AND ANTIVIRAL COMPOUNDS BASED ON CYANINES PCT PCT PCT/US2023/081638 Pending
NEI E-153-2020-0-CA-04 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells CA National Stage 3220433 Pending
NCI E-046-2019-1-US-01 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS US CON 18/520,027 Pending
NEI E-155-2020-0-JP-06 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS JP National Stage 2023-572794 Pending
NEI E-153-2020-0-JP-05 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS JP National Stage 2023-572792 Pending
NIDDK E-112-2021-0-US-02 VITAMIN C RENAL LEAK AS A CLINICAL DIAGNOSTIC TOOL IN THE DETECTION, MONITORING, AND MANAGEMENT OF ACUTE AND CHRONIC DISEASES US National Stage 18/563,663 Pending
NHLBI E-127-2021-2-CN-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES CN National Stage 202280037094.2 Pending
NCI E-171-2018-7-EP-01 MODIFIED CELLS AND METHODS OF THERAPY EP DIV 23211577.4 Pending
NCI E-174-2018-2-EP-01 TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY EP DIV 23211578.2 Pending
NCI E-101-2021-0-EP-08 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 EP National Stage 22726335.7 Pending
NICHD E-028-2020-0-US-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING US National Stage 18/563,237 Pending
NEI E-155-2020-0-US-02 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS US National Stage 18/562,806 Pending
NCI E-191-2019-0-EP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION EP National Stage 22721599.3 Pending
NEI E-155-2020-0-CA-05 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS CA National Stage 3220602 Pending
NCI E-027-2023-0-PC-01 REAL-TIME REMOTE CONTROLLED MICROSCOPY AND COMMUNICATIONS OVER A NETWORK PCT PCT PCT/US2023/079836 Pending
NIAAA E-087-2021-0-US-02 A FACILE AND ODOR-FREE APPROACH TO CONVERT SULFONYL UREA DERIVATIVES TO CHALCOGENIDE SULFONYL UREA DERIVATIVES US National Stage 18/561,068 Pending
NCI E-239-2017-0-NZ-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS NZ DIV 805541 Pending
NCI E-065-2021-0-CN-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF CN National Stage 202280034971.0 Pending
NCI E-096-2021-0-US-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS US National Stage 18/290,442 Pending
NEI E-153-2020-0-US-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells US National Stage 18/290,396 Pending
NCI E-219-2022-0-US-02 CIRCULATING miRNA MARKERS FOR DETECTION OF RADIATION EXPOSURE US ORD 18/507,575 Pending
NCATS E-039-2021-0-JP-01 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION JP National Stage 2023-557052 Pending
NCI E-264-2011-0-US-02 DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS US CON 18/507,690 Abandoned
NINDS E-018-2024-0-PCT-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA PCT PCT PCT/US2023/079547 Pending
NIA E-062-2021-0-EP-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE EP National Stage 22722061.3 Pending
NEI E-153-2020-0-AU-03 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells AU National Stage 2022282379 Pending
NEI E-155-2020-0-AU-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS AU National Stage 2022280062 Pending
NHLBI E-127-2021-2-US-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES US National Stage 18/560,035 Pending
NIAID E-205-2024-1-US-01 Human Protective Neutralizing and Non-Neutralizing Antibodies and Their Use Against Influenza Viruses US 63/597,463 Pending
NHLBI E-166-2022-0-PC-01 MYOTOMY CATHETER SYSTEM AND METHODS FOR A MYOTOMY CATHETER SYSTEM PCT PCT PCT/US2023/079114 Pending
NCI E-017-2023-0-PC-01 Directed acetylation of mRNA through engineered snoRNA adapters PCT PCT PCT/US2023/078830 Pending
NCI E-101-2021-0-US-07 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 US National Stage 18/289,596 Pending
NCI E-291-2012-0-US-25 M971 CHIMERIC ANTIGEN RECEPTORS US CON 18/503,107 Pending
NCI E-291-2012-0-US-26 M971 CHIMERIC ANTIGEN RECEPTORS US CON 18/502,993 Pending
NCI E-009-2023-0-PC-01 IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OFCANCER AND MYELOID-MEDIATED DISEASES PCT PCT PCT/US2023/078854 Pending
NCI E-101-2021-0-JP-02 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 JP National Stage 2023-568469 Pending
NHLBI E-127-2021-2-IL-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES IL National Stage 308337 Pending
NIAID E-149-2022-0-PC-01 NOVEL ANTIBODIES FOR HIV AND METHODS OF MAKING AND USING SAME PCT PCT PCT/US2023/078631 Pending
NCI E-172-2020-0-HK-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION HK EP 62023081975.2 Pending
NCI E-105-2023-0-US-01 DNA methylation-based cancer diagnostics US ORD 18/499,833 Pending
NCI E-118-2021-0-AU-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors AU National Stage 2022291120 Pending
NCI E-285-2016-2-US-01 Glypican 2 As A Cancer Marker And Therapeutic Target US DIV 18/499,054 Pending
NCI E-206-2022-0-PC-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PCT PCT PCT/US2023/078190 Pending
NIAID E-153-2023-0-PC-01 Rebalancing the Immune System Through Depletion of Myeloid-Biased Hematopoietic Stem Cells PCT PCT PCT/US2023/036280 Pending
NCI E-213-2022-0-PC-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PCT PCT PCT/US2023/078156 Pending
NCI E-013-2024-0-US-01 Human glioblastoma enriched lipids that can stimulate NKT cells US 63/546,349 Expired
NCI E-101-2021-0-CA-03 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 CA National Stage 3217263 Pending
NCI E-099-2021-0-US-02 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE US National Stage 18/557,741 Pending
NIAID E-239-2020-0-CN-01 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE CN National Stage 202280031803.6 Pending